It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
One of the ultimate goals of regenerative medicine is the generation of patient-specific organs from pluripotent stem cells (PSCs). Sheep are potential hosts for growing human organs through the technique of blastocyst complementation. We report here the creation of pancreatogenesis-disabled sheep by oocyte microinjection of CRISPR/Cas9 targeting PDX1, a critical gene for pancreas development. We compared the efficiency of target mutations after microinjecting the CRISPR/Cas9 system in metaphase II (MII) oocytes and zygote stage embryos. MII oocyte microinjection reduced lysis, improved blastocyst rate, increased the number of targeted bi-allelic mutations, and resulted in similar degree of mosaicism when compared to zygote microinjection. While the use of a single sgRNA was efficient at inducing mutated fetuses, the lack of complete gene inactivation resulted in animals with an intact pancreas. When using a dual sgRNA system, we achieved complete PDX1 disruption. This PDX1−/− fetus lacked a pancreas and provides the basis for the production of gene-edited sheep as a host for interspecies organ generation. In the future, combining gene editing with CRISPR/Cas9 and PSCs complementation could result in a powerful approach for human organ generation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of California Davis, Department of Animal Science, Davis, United States (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
2 School of Medicine, Stanford University, Institute for Stem Cell Biology and Regenerative Medicine, Stanford, United States (GRID:grid.168010.e) (ISNI:0000000419368956); King’s College, Centre for Stem Cells & Regenerative Medicine and Institute for Liver Studies, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 School of Medicine, Stanford University, Institute for Stem Cell Biology and Regenerative Medicine, Stanford, United States (GRID:grid.168010.e) (ISNI:0000000419368956)
4 School of Veterinary Medicine, University of California Davis, Department of Population Health and Reproduction, Davis, United States (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
5 College of Biological Sciences, University of California Davis, Department of Neurobiology, Physiology & Behavior, Davis, United States (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
6 California Animal Health and Food Safety Laboratory, University of California Davis, Davis, Davis, United States (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)